Bank of America Reaffirms Underperform Rating for Alkermes (NASDAQ:ALKS)

Posted by Francis Steltz on Jun 29th, 2026

Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “underperform” rating reissued by analysts at Bank of America in a research note issued on Monday,Benzinga reports.

ALKS has been the subject of a number of other reports. Needham & Company LLC increased their price objective on Alkermes from $54.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Piper Sandler cut their price objective on Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a research report on Tuesday, March 24th. HC Wainwright reaffirmed a “neutral” rating on shares of Alkermes in a research note on Thursday, June 18th. Robert W. Baird lifted their target price on shares of Alkermes from $45.00 to $48.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Finally, UBS Group upped their price target on shares of Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.06.

Check Out Our Latest Report on Alkermes

Alkermes Price Performance

ALKS opened at $55.08 on Monday. The firm has a market cap of $9.18 billion, a price-to-earnings ratio of 61.20 and a beta of 0.38. The company’s 50-day moving average price is $39.79 and its 200 day moving average price is $34.03. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $55.28. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.85.

Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported $0.29 earnings per share for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%.The business had revenue of $384.55 million for the quarter. As a group, sell-side analysts expect that Alkermes will post -0.43 earnings per share for the current year.

Insider Activity

In other Alkermes news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.20, for a total value of $67,528.80. Following the transaction, the executive vice president owned 231,558 shares in the company, valued at approximately $7,687,725.60. This represents a 0.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $35.51, for a total transaction of $319,590.00. Following the transaction, the executive vice president owned 85,389 shares in the company, valued at approximately $3,032,163.39. This represents a 9.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 35,102 shares of company stock worth $1,310,828 in the last 90 days. Company insiders own 4.59% of the company’s stock.

Institutional Trading of Alkermes

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cullen Frost Bankers Inc. acquired a new stake in Alkermes during the fourth quarter valued at $28,000. Johnson Financial Group Inc. acquired a new position in Alkermes in the 3rd quarter worth about $31,000. UMB Bank n.a. increased its position in Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after purchasing an additional 446 shares during the last quarter. Salomon & Ludwin LLC increased its position in Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock worth $35,000 after purchasing an additional 667 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Alkermes by 1,041.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock valued at $37,000 after buying an additional 1,208 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Company Profile

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.